Martijn Kedde

Title: Martijn Kedde: Innovator in AML Therapeutics

Introduction

Martijn Kedde is a notable inventor based in Amsterdam, Netherlands. He has made significant contributions to the field of therapeutics, particularly in the treatment of acute myeloid leukemia (AML). With a total of 4 patents, Kedde's work focuses on developing innovative solutions for combating myeloproliferative and lymphoproliferative disorders.

Latest Patents

Kedde's latest patents include groundbreaking inventions aimed at addressing AML. One of his notable patents is titled "Means and methods for counteracting myeloproliferative or lymphoproliferative disorders." This invention provides human AML-specific binding compounds that can effectively bind to a cell surface component of AML cells. Additionally, it outlines therapeutic uses of these binding compounds against AML. Another significant patent is "AML antigens and uses thereof," which presents novel compounds comprising an antigen of AML cells and their various applications.

Career Highlights

Throughout his career, Martijn Kedde has worked with several prominent companies in the biotherapeutics sector. He has been associated with Kling Biotherapeutics B.V. and Aimm Therapeutics B.V., where he has contributed to the advancement of therapeutic solutions for cancer treatment.

Collaborations

Kedde has collaborated with esteemed colleagues in his field, including Hergen Spits and Marijn Aletta Gillissen. These collaborations have further enriched his research and development efforts in the realm of AML therapeutics.

Conclusion

Martijn Kedde stands out as an innovative inventor dedicated to improving treatments for AML. His patents and collaborations reflect his commitment to advancing medical science and providing hope for patients affected by this challenging disease.